TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9337828
Drug: Exhalation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exhalation at an expiratory flow rate of 1100 ml/min
Study: 1426295
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE)
Study: 30626496
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy plus usual care
Study: 29178728
Drug: Higher abrasivity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher abrasivity daily-use whitening dentifrice (1,100 ppm fluoride as sodium fluoride; RDA137)
Study: 24014214
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg/day for 5 days plus uFSH 37.5 IU/day
Study: 18751491
Drug: Surgical hand
Normalized name: ALCOHOL 75 mL in 100 mL Topical GEL [Wash-Free Surgical Hand Disinfectant Gel II]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical hand antisepsis solutions (specific solutions not mentioned)
Study: 12865477
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (80 mg twice daily)
Study: 8694165
Drug: Syntocinon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntocinon (1 ml, 10 units)
Study: 8694165
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml, placebo)
Study: 1905592
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 180 mg b.i.d.
Study: 6410280
Drug: Drug counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug counseling alone (DC)
Study: 31868694
Drug: Horse-riding therapy
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-riding therapy (H-RT)
Study: 31868694
Drug: Rhythm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm and music-based therapy (R-MT)
Study: 29311155
Drug: Sitagliptin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin therapy
Study: 27095003
Drug: Human α1-antitrypsin
Normalized name: herpesvirus 1, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human α1-antitrypsin (A1AT) 240 mg/kg
Study: 19786415
Drug: Escitalopram during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram during intravenous interferon-alpha therapy
Study: 19786415
Drug: Methylphenidate during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate during intravenous interferon-alpha therapy
Study: 19786415
Drug: Escitalopram and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram and methylphenidate together during subcutaneous interferon therapy
Study: 19786415
Drug: Alternate agent
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate agent alone during subcutaneous interferon therapy
Study: 17514589
Drug: Hypoglycemia (induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (induced by insulin 0.1 IU/kg intravenously)
Study: 17514589
Drug: Apomorphine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.75 mg subcutaneously)
Study: 17514589
Drug: Hypoglycemia (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (after previous treatment with apomorphine)
Study: 19348328
Drug: Curosurf administration
Normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curosurf administration
Study: 16957969
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection of 99mTc-sulfur colloid
Study: 16957969
Drug: Intraparenchymal (IP)
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal (IP) injection of 99mTc-sulfur colloid
Study: 16957969
Drug: Subareolar (SA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subareolar (SA) injection of 99mTc-sulfur colloid
Study: 10831163
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.125 IU/kg/wk for 4 weeks, then 0.25 IU/kg/wk for 6 months)
Study: 6368753
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of diazepam 20 mg
Study: 6368753
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diazepam 20 mg
Study: 25427598
Drug: Thiopental (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4 mg/kg IV)
Study: 25427598
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg IV)
Study: 24227734
Drug: Responses to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responses to body effectors (e.g., hands, feet, limbs) in lateral occipitotemporal cortex (LOTC) and parietal cortex.
Study: 21848497
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal estradiol (E2) gel (0.9 g/day, containing E2 0.54 mg/day)
Study: 19214559
Drug: Treatment-related factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related factors
Study: 11869171
Drug: Glibenclamide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (10 mg day-1)
Study: 11869171
Drug: Acarbose (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (300 mg day-1)
Study: 2738909
Drug: Alpha-gliadin antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-gliadin antibodies (AGA) of subclasses IgG1 and IgG3 in coeliac patients
Study: 29278929
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg orally (PO)
Study: 29278929
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg PO
Study: 9263186
Drug: Mineral group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral group: 20 mg zinc, 100 micrograms selenium
Study: 9263186
Drug: Vitamin group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin group: 120 mg vitamin C, 6 mg beta‐carotene, 15 mg vitamin E
Study: 9263186
Drug: Mineral and
Normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 15.2 g in 100 g TOPICAL STICK [Dove Men plus Care Elements Mineral and Sage Antiperspirant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral and vitamin group: Zn 20 mg, Se 100 micrograms, Vit C 120 mg, beta CA 6 mg, Vit E 15 mg
Study: 21548978
Drug: Flexible nasendoscope
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible nasendoscope with gel cap
Study: 21548978
Drug: Flexible nasendoscope
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible nasendoscope without gel cap (control)
Study: 12584786
Drug: Rhubarb treatment
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb treatment
Study: 16787193
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day) for 7 days
Study: 12672280
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) assessment
Study: 7742052
Drug: Prophylactic somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic somatostatin (4.5 mg daily in continuous perfusion for 7 days postoperatively)
Study: 31657637
Drug: 750-g ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750-g ice bag applied for 10 to 60 minutes based on subcutaneous adipose thickness
Study: 28178599
Drug: Dexpramipexole (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (50mg to 300mg daily)
Study: 18071079
Drug: Quinapril, target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril, target dose 40 mg/d
Study: 12672922
Drug: Sprinkles containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles containing 80 mg iron and 10 mg zinc (FeZn)
Study: 12672922
Drug: Sprinkles containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles containing 80 mg iron (Fe)
Study: 8729205
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate (1.34 mg)
Study: 26984569
Drug: 12-month physical
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month physical exercise program, 40 minutes twice weekly for 1 year
Study: 22025490
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion with ropivacaine 2 mg/mL at 5 mL/h for 48 hours
Study: 22025490
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 2 mg every 12 hours for 48 hours
Study: 22025490
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion with ropivacaine
Study: 20811292
Drug: CC+CT genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+CT genotype of rs2006765
Study: 18642564
Drug: Cytotec (Misoprostol)
Normalized name: misoprostol Oral Tablet [Cytotec]
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytotec (Misoprostol) oral application (50 microg every 4 hours, max 200 microg)
Study: 18642564
Drug: Cytotec (Misoprostol)
Normalized name: misoprostol Oral Tablet [Cytotec]
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytotec (Misoprostol) vaginal application (two doses of 50 microg every 6 hours)
Study: 9598451
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (1.07 mg/kg mefloquine, 2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Study: 9598451
Drug: Sulfadoxine/pyrimethamine (2.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine (2.14 mg/kg sulfadoxine, 0.11 mg/kg pyrimethamine)
Study: 9598451
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (1.07 mg/kg)
Study: 3280128
Drug: Biperiden (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (5.0 mg)
Study: 3280128
Drug: Clonazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1.0 mg)
Study: 3280128
Drug: Lisuride (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.05 mg)
Study: 25829103
Drug: Psycho-education combined
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-education combined with pharmacotherapy
Study: 21138825
Drug: Exenatide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide, 10 µg twice daily for 30 weeks
Study: 18822845
Drug: Combination pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pharmacotherapy with antihypertensive drugs
Study: 16847290
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg, uptitrated to 15 mg if necessary)
Study: 10320243
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (group MP)
Study: 10320243
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (group NS)
Study: 1924643
Drug: Nicotine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (single dose)
Study: 1924643
Drug: Scopolamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (single dose)
Study: 27426024
Drug: Yoga training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga training (60-min classes weekly for six months)
Study: 15969863
Drug: Pre-treatment erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment erythropoietin levels
Study: 12870985
Drug: Ferric sulphate
Normalized name: Ferric Oxide
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric sulphate (FS) 15.5% solution applied for 15 seconds
Study: 2025573
Drug: Daunorubicin, cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin, cytosine arabinoside and thioguanine combination
Study: 30199128
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (SP)
Study: 26136435
Drug: Orofacial Myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orofacial Myofunctional Therapy (OMT)
Study: 22914255
Drug: Polyphenol-rich olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich olive oil (∼30 mg/day)
Study: 18561116
Drug: Neuromonics Tinnitus
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromonics Tinnitus Treatment (customized neural stimulus)
Study: 18561116
Drug: Neuromonics Tinnitus
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromonics Tinnitus Treatment
Study: 15809910
Drug: ORS with
Normalized name: SODIUM FLUORIDE 2.43 mg in 1 g ORAL PASTE, DENTIFRICE [Dr Tichenors With Extra Whitening and Tartar Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS with L-histidine (2.5 g/L)
Study: 15809910
Drug: ORS without
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS without L-histidine
Study: 12398233
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (Ortho Tri-Cyclen: norgestimate and ethinylestradiol)
Study: 10605165
Drug: Lamotrigine monotherapy
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine monotherapy (206.4 ± 44.4 mg/day)
Study: 10605165
Drug: Lamotrigine combined
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine combined with carbamazepine (1208 ± 82.9 mg/day + 561.7 ± 76.8 mg/day)
Study: 1659440
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ml‐1 443C81
Study: 1659440
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ml‐1 443C81
Study: 7037414
Drug: Oxprenolol 40
Normalized name: oxprenolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 40 mg b.d.
Study: 30273200
Drug: Ultra-low-dose IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose IT naloxone (20 μg) and IT morphine (0.2 mg)
Study: 30273200
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine (0.2 mg) alone
Study: 31003657
Drug: Active video
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active video game intervention (twice a week for 45 minutes over eight weeks)
Study: 25542616
Drug: Neutral shampoo
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral shampoo eyelid hygiene plus topical metronidazole gel 0.75% twice/day
Study: 25542616
Drug: Neutral eyelid
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral eyelid hygiene with shampoo plus neomycin 3.5% and polymyxin 10% antibiotic ointment with 0.5% dexamethasone 3 times/day
Study: 18288078
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg p.o.)
Study: 18288078
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg p.o.)
Study: 12757769
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OAC) with a target INR of 2.0-2.5 and aspirin 75 mg/day
Study: 3613407
Drug: Heparin free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin free hemodialysis
Study: 3613407
Drug: Systemic heparinization,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparinization, intermittent saline flushes, and constant saline infusions
Study: 30368509
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with S-1
Study: 30368509
Drug: Alternate-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day treatment with S-1
Study: 22918663
Drug: Full mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full mouth non‐surgical periodontal therapy followed by open flap surgery
Study: 16114063
Drug: Clover phytoestrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clover phytoestrogens 240 mg daily for 2 weeks
Study: 14526951
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion rates measured in microg U g(‐1) creatinine for 1997 and 1999.
Study: 10971313
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (loading dosage and constant infusion)
Study: 20012601
Drug: Oral lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lovastatin (20 mg)
Study: 8617086
Drug: PGI2 (Prostacyclin)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 (Prostacyclin) at a dose of 2 to 12 ng/kg/min, IV, infused continuously for 48 h
Study: 1548451
Drug: Caffeine 178
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 178 mg
Study: 1548451
Drug: Caffeine doses
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine doses (100 mg, 56 mg, 32 mg, 18 mg, 10 mg)
Study: 2984846
Drug: 0.28 ml
Normalized name: ethanol 0.28 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.28 ml of Rh-positive red cells (challenge)
Study: 23141144
Drug: Clobazam at
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam at dosages ≤2.0 mg/kg/day (≤80 mg/day)
Study: 20979934
Drug: Probenecid (PRB)
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid (PRB) co-administered with Mizoribine (MZR)
Study: 12798283
Drug: Glucose 100
Normalized name: glucose 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 100 mg/kg
Study: 12798283
Drug: Glucose 500
Normalized name: glucose 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 500 mg/kg
Study: 12798283
Drug: Glucose 50
Normalized name: glucose 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 50 g
Study: 12798283
Drug: Placebo (23.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (23.7 mg saccharin)
Study: 8961362
Drug: 44 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 Gy in 16 daily fractions of radiation therapy (RT)
Study: 8144848
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment alone
Study: 8144848
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + LHRHa treatment
Study: 3529772
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of heparin + 0.5 mg dihydroergotamine (HDHE) s.c. every 12 hours
Study: 3529772
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of heparin (LDH) s.c. every 8 hours
Study: 19167589
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg QD
Study: 15938887
Drug: Before tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before tooth preparation and 3 months after fixed prosthesis insertion
Study: 15320851
Drug: Combination ARB/ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ARB/ACE inhibitor therapy
Study: 15320851
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor therapy alone
Study: 8029088
Drug: Buserelin, 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin, 1800 micrograms/day as nasal spray
Study: 8029088
Drug: Triptorelin Depot,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin Depot, 3.75 mg/every 4 weeks i.m.
Study: 2567345
Drug: SKF 39393
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 39393 (selective D-1 dopamine receptor agonist) at daily doses ranging from 3.2 to 32 mg/kg over treatment intervals of one to seven weeks.
Study: 1153447
Drug: Ethanol self-administration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol self-administration (8 drinks of ethanol, 89.12 g total)
Study: 1153447
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice self-administration (8 drinks of orange juice)
Study: 30629160
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy including mineralocorticoid receptor antagonists, statins, ACE inhibitors and/or receptor blockers, and cardiac rehabilitation.
Study: 26173635
Drug: CRT-D treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D treatment effect by LVEF interaction
Study: 21520154
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers PSMA, PSGR, and PCA3 detected by quantitative real-time PCR in post-PM urine sediment.
Study: 18316236
Drug: Involuntary movements
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary movements concurrent to speech